Storia in 9 fonti

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

Shares in biotechnology company Apogee Therapeutics (APGE) are set to start the new week off in great shape on reports that it could be swallowe...

Raccontata da

markets.businessinsider.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

markets.businessinsider.comStai leggendo1 mese fa

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

AbbVie acquires Apogee Therapeutics for $11B; zumilokibart for atopic dermatitis requires fewer injections than competitor Dupixent. Differentiates in 200M+ AD market via injection frequency—improves patient compliance and extends franchise lifetime value.

originale

Timeline cronologica

venerdì 19 giugno 2026·markets.businessinsider.com
M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
Shares in biotechnology company Apogee Therapeutics (APGE) are set to start the new week off in great shape on reports that it could be swallowe...
venerdì 19 giugno 2026·wiwo.de
Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics
Der Pharmariese aus den USA plant offenbar den Kauf von Apogee Therapeutics. Das Angebot stellt einen deutlichen Aufschlag dar.

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

Confronto fonti

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

Timeline cronologica

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics

Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics

AbbVie to buy Apogee Therapeutics in nearly $11B deal

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics

AbbVie ultima la compra de la 'biotech' Apogee por 9.500 millones

AbbVie ultima la compra de la 'biotech' Apogee por 9.500 millones

FT: AbbVie está perto de comprar Apogee Therapeutics por US$ 11 bi

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

AbbVie to buy Apogee Therapeutics in nearly $11B deal

Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar

AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther

AbbVie Goes On The Offensive With $10.9 Billion Takeover

AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares